Stockreport

Adverum Biotechnologies Presents Additional Long-term Preclinical Data on ADVM-022 in Wet AMD at ASGCT 21st Annual Meeting

Adverum Biotechnologies, Inc.  (ADVM) 
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: adverum.gcs-web.com/investor-overview
PDF -- Single Intravitreal Administration of Gene Therapy ADVM-022 ProvidesLong-term Protection in Nonhuman Primate Model of Wet AMD -- MENLO PARK, Calif., May 17, 2018 [Read more]